Clinical Trials Browser

OTHER × efineptakin alfa × Clear all

NCT07052305 2026-02-12

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT05286060 2026-02-09

GENUINE

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma, Gliosarcoma

NCT03687957 2025-11-25

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Phase 1/2 Active not recruiting

42 enrolled 19 charts

Glioma

NCT07200089 2025-09-30

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Phase 1 Not yet recruiting

Multiple Myeloma

NCT04588038 2025-02-14

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT04893018 2024-06-27

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Phase 1 Terminated

8 enrolled 14 charts

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi, HIV Infections

NCT02659800 2023-10-06

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Phase 1 Terminated

Glioma, Lymphopenia

NCT03206138 2017-07-02

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Phase NA Unknown

Uterine Cervical Dysplasia